Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779483 | 0.78 | BCHE (0.33) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL8777267 | 0.77 | KCNH2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL5466444 | 0.76 | MAPT (0.38) | MAPTALDH1A1HTTSMN1; SMN2NPC1 | |
| SCHEMBL2900368 | 0.75 | ALDH1A1 (0.34) | ALDH1A1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL5777073 | 0.75 | RAB9A (0.56) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL17001546 | 0.74 | ALDH1A1 (0.40) | MAPTALDH1A1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3932788 | 0.74 | SMYD2 (0.32) | ALDH1A1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL875044 | 0.74 | BACE1 (0.39) | ALDH1A1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL5778911 | 0.74 | MAPT (0.32) | MAPT | |
| SCHEMBL4116949 | 0.73 | SMYD2 (0.31) | CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | HTR2B 1280/4885MAPT 94/4885ALDH1A1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.